DALLAS-FORT WORTH, Texas, Aug. 02, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a
pharmaceutical company focused on developing and commercializing innovative extended-release (XR) products for the treatment of
attention-deficit/hyperactivity disorder (ADHD), today announced that it will report second quarter 2016 financial results on
Thursday, August 11, before the market opens. Management will host a conference call beginning at 8:30 a.m. Eastern Time that
day to review results and provide a company update.
To access the call, dial 877-388-8985 (U.S.) or 562-912-2654 (outside of the U.S.). The Conference ID is
49610681. A live webcast will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/. Please log in approximately 5-10 minutes prior to the scheduled
start time.
The archived webcast will be available on the company’s Investor Relations page under Presentations.
About Neos Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its
proprietary modified‐release drug delivery technology platforms. Adzenys XR-ODT is the first approved product using the Company’s
XR-ODT technology platform. Neos, which is initially focusing on the treatment of ADHD, has two other branded product candidates
that are XR medications in ODT or liquid suspension dosage forms. In addition, Neos manufactures and markets its generic equivalent
of the branded product Tussionex®, an XR liquid suspension of hydrocodone and chlorpheniramine indicated for the relief of cough
and upper respiratory symptoms of a cold.
1Tussionex® is a registered trademark of the UCB Group of Companies
CONTACTS: Richard I. Eisenstadt Chief Financial Officer Neos Therapeutics (972) 408‐1389 reisenstadt@neostx.com David Carey, Investor Relations Lazar Partners (212) 867‐1768 dcarey@lazarpartners.com
